INTRODUCTION
Retinoids are signaling molecules that are structural and functional derivatives of vitamin A (retinol). The term collectively describes naturally occurring retinol and its metabolites, as well as synthetic analogs. Retinoid receptors are found ubiquitously in virtually all organ systems, and they regulate important functions in the body, including embryonic development, vision, immune and neural function, as well as cell proliferation, differentiation, and apoptosis. 1, 2 These compounds exert their effects through control of gene expression. In the treatment of cancer, the retinoids are considered "biologic response modifiers" (BRMs) in that they are dissimilar to traditional cytotoxic chemotherapy, inducing response without immune suppression, and often augmenting the immune response. [3] [4] [5] Although there have been a number of clinical studies using retinoids for treatment of breast, ovarian, renal, head and neck, melanoma, and prostate cancers, they are most prominently used in the treatment of hematologic malignancies. In the case of acute promyelocytic leukemia, retinoids in the form of all-trans retinoic acid are used as first-line treatment to restore normal myeloid differentiation to leukemic cells, inducing the formation of mature granulocytes. 6 In T-cell lymphoma cells, retinoids are thought to induce apoptosis and DNA fragmentation in affected T lymphocytes. 7, 8 Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of uncommon primarily mature T-helper lymphoproliferative disorders. The most common form is mycosis fungoides (MF), which accounts for approximately 60% of all cases. 9 It typically displays indolent behavior, although disease progression to higher stages or transformation to large-cell lymphoma can occur. Sé zary syndrome (SS) is a related subtype of CTCL presenting as erythroderma, with a significant population of circulating atypical T-lymphocytes and typically has a more aggressive course than MF. Patients with the earliest stages of MF do not have decreased survival due to their disease, and skin-directed therapy, such as phototherapy or topical medications, are the mainstays of treatment. 10 Additionally, treatment with BRMs, such as interferons or retinoids, also are commonly used in these patients, although systemic treatment is generally reserved for patients with MF who have failed local or skin-directed therapy or have more extensive disease. 5, 10 The anecdotal use of retinoids for treatment of MF was first reported in the 1980s, both as monotherapy or in combination with chemotherapy. 3, 11, 12 Currently, topical and systemic retinoids are an integral part of the treatment armamentarium for CTCL. This article focuses primarily on systemic retinoids in MF and SS.
RETINOIDS AND MECHANISM OF ACTION
All retinoids have similar molecular structure, containing a benzene ring, a polyene chain, and a carboxylic end group. In the body, retinol is metabolized to all-trans retinoic acid and then further isomerizes to 13-cis retinoic acid (isotretinoin) and 9-cis retinoic acid in the liver. 2 Subsequently, synthetic retinoids have been derived from retinol, including mono-aromatic second-generation retinoids (eg, etretinate, acitretin) followed by polyaromatic third-generation compounds called arotenoids (eg, bexarotene). 13 More recently, alitretinoin, which is a synthetic analog of 9-cis retinoic acid, has been developed with efficacy in atopic dermatitis and a few reports showing effects in MF/SS.
Retinoids bind to 2 distinct families of nuclear receptors regulating gene transcription called retinoic acid receptors (RARs) and retinoic X receptors (RXRs). Each receptor is associated with 3 subtypes, a, b, and, g, which bind to specific ligands. 1, 14 These receptors are part of a larger superfamily of nuclear receptors, including thyroid hormone receptor, vitamin D3 receptor, and glucocorticoid receptor ( Table 1) .
1 Transactivation of some of these other nuclear receptors is believed to be linked to some of the side effects seen with the retinoids. 1 Despite significant progress in elucidating the mechanism by which retinoids exert their activity, their effect on tumorigenesis and cancer biology remains poorly understood. The RAR receptors bind only to all-trans retinoid acid, 9-cis retinoic acid or synthetic isotretinoin, etretinate, and acitretin. The RXR receptors exclusively bind to 9-cis retinoic acid or synthetic retinoids such as bexarotene (which is often referred to as a rexinoid). 3, 15 These receptors can form homodimers or heterodimers with each other or with other nuclear hormone receptors, such as thyroid hormone receptor or liver X receptor. The RXR receptor also can form a tetramer in its resting state. Once bound to a ligand, the receptor induces a conformation change forming a ligand-receptor complex. These complexes bind directly to specific DNA sequences called hormone response elements that affect transcription of specific genes and production of specific peptides downstream, which can induce and maintain terminal differentiation of malignant cells.
1,16 Fig. 1 is a diagram demonstrating possible combinations of receptor dimers formed by rexinoid receptors.
Retinoids also have been shown to inhibit ornithine decarboxylase activity, an enzyme that is upregulated in the presence of tumor-promoting substances. 17 It is believed that retinoids also promote the production of gap junctions, which are lost during malignant transformation, as well as their glycoproteins, which aid in cell communication, adhesion, and growth. 16 Rexinoids, such as bexarotene, bind exclusively to the RXR, and its activation has been shown to induce apoptosis involving activation of the caspase pathway. Bexarotene has been shown to activate caspase-3, a key executor of the apoptotic pathway, with resultant apoptosis as evidenced by increased poly (ADP-Ribose) polymerase and downregulation of survivin (a suppressor of caspase-induced apoptosis). 8 Retinoids reduce expression of Bcl-2 protein and upregulate bax proteins, which also are involved in apoptotic pathways. 18 Activation of RXR receptor also has been associated with activation of p53, a tumor suppressor protein, by facilitating its binding to promoters leading to cell cycle arrest. 19 Other antitumor effects of rexinoids include reduction in matrix metalloproteinases, vascular endothelial growth factor, and epidermal growth factor, which are important factors in angiogenesis as well as tumor cell migration and invasion. 20 Various investigators have reported the immunomodulatory effects of retinoids and rexinoids. RARs are constitutively expressed in human T and B lymphocytes. Activation of RAR g has been shown to promote CD81 T-cell responses. 15 Retinoids upregulate Langerhans cell antigen presentation and surface expression of HLA-DR and CD11c, which is important for T-cell activation. 21 Retinoids and rexinoids also have been shown to upregulate interleukin-2 receptor (IL-2R) expression with associated increase in interferon (IFN) g levels. 22 Gorgun and Foss 4 reported elevation in IL-2R levels in human T-cell and B-cell leukemia cell lines after treatment with rexinoids. In the same study, they reported the upregulation of IL-2R in the malignant cells translated to increase sensitivity to denileukin diftitox (a fusion protein of diphtheria toxin bound to the ligand for the IL-2R previously used in the treatment of CTCL).
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RETINOIDS IN CUTANEOUS T-CELL LYMPHOMA
Currently all systemic retinoids in use for CTCL are oral agents (administered with food for optimal absorption). Isotretinoin was the first retinoid used for the off-label treatment of CTCL. In 1983, Kessler and colleagues 11 first reported activity in 4 patients with MF treated with isotretinoin at doses of 1 to 3 mg/kg per day with response seen in all patients, 1 patient with a complete response (CR). The investigator proceeded to study 21 additional patients with plaque, tumor, and erythrodermic MF, including 5 with SS using doses of 1 to 2 mg/kg per day. 24 Forty-four percent of patients were reported to have a clinical response, but most patients required dosage adjustment because of mucocutaneous side effects. 24 In 2005, Leverkus and colleagues 25 reported effective treatment of folliculotropic MF with isotretinoin at up to 1 mg/kg per day with specific regard to miniaturization of cysts and comedones associated with this subtype. This effect may be due to the strong affinity of isotretinoin for the pilosebaceous unit. Higher doses of isotretinoin (eg, >1 mg/kg per day) produced similar response rates with higher rates of toxicity compared with 1 mg/kg per day. 24 Overall, use of isotretinoin in MF/SS resulted in clinical responses of 43% to 100% with CR rates of typically less than 20% and short response duration ranging from 3 to 15 months. 3 Etretinate was the second retinoid approved for clinical applications, originally approved for use in psoriasis. It is highly lipophilic and has a significantly longer half-life of more than 120 days compared with 21 hours with isotretinoin and requires 2 or more years to be completely eliminated from the body after completion of treatment. As such, it was replaced by its metabolite acitretin with a shorter half-life of 2 to 4 days and an elimination period of approximately 2 months (though alcohol ingestion can cause acitretin to convert to etretinate and should be avoided during acitretin use). 26 Before the withdrawal of etretinate from the market in 1998, several studies reported responses in patients with MF when used off-label. Claudy and colleagues 27 treated 12 patients with etretinate monotherapy using 0.8 to 1.0 mg/kg per day with response seen in all patients, but only 1 patient achieved a CR. Clinical response was seen in 55% of patients treated with etretinate in a larger study of 29 patients reported by Molin and colleagues 28 with CR seen in only 1 patient. The treatment response with etretinate appears to be similar to that reported with isotretinoin.
Cheeley and colleagues 29 reported a retrospective study on the use of acitretin in 32 patients with MF/SS. There was a 59% overall response rate with 1 patient achieving CR, but the interpretation of these results may be confounded by other concomitant treatments received by the patients. Acitretin was used as monotherapy in only 6 patients with MF in the study, with clinical response seen in approximately 25% of these patients. The investigators in the retrospective review attempted to compare response between acitretin and bexarotene in patients treated with both medications at different times in their treatment course, but timing of use in the disease course and other concomitant treatment may influence therapeutic outcome, making comparison difficult. There is limited experience with acitretin in MF (doses used typically 10-50 mg daily), but anecdotal evidence suggests that it may be less effective in these patients than the other RAR agonists or bexarotene, but few comparative studies exist.
1 Alltrans retinoic-acid has been shown in vitro to have beneficial effects in CTCL and has also been used off-label for CTCL. 30, 31 Bexarotene is a synthetic rexinoid with RXR selective binding. Unlike its predecessor retinoids, it was approved by the Food and Drug Administration (FDA) specifically for the treatment of CTCL in 1999. Bexarotene was investigated in 2 phase II-III trials in 58 patients with early-stage (I-IIA) MF and in 94 patients with advanced-stage (IIB-IVB) MF/SS. 32, 33 In the early-stage trial, patients were treated at dosages ranging from 6.5, 300, and 650 mg/m 2 per day, but the 300 mg/m 2 per day dosage was found to be the ideal starting dose due to toxicity. 3 Clinical responses in this study were reportedly 20%, 54%, and 67% in the 6.5, 300, and 650 mg/m 2 per day treatment groups, respectively. 32 Of the advanced-stage patients, 56 were treated at a dosage of 300 mg/m 2 per day and 38 at a dosage of more than 300 mg/m 2 per day. Patients treated at 300 mg/m 2 per day had clinical responses in 45% (25 of 56) of patients compared with 55% (21 of 38) of patients in the higher-dose treatment group, suggesting that there is a dose-related treatment response. The CR rates for the 300 mg/m 2 per day group was 2% compared with 13% in the higher-dose group. The median time to response was 180 days and time to progression was projected to be 299 days for the lower-dose group and 385 days for the higher-dose group. Among patients with a history of previous retinoid therapy who had not previously responded to other retinoids or had previously responded but progressed, a large portion (54%) improved with bexarotene. More adverse reactions were reported in the higher-dose group with approximately13% of patients in this group discontinuing treatment because of side effects compared with 7% in the lower-dose group. 33 Another large retrospective trial was reported by Abbott and colleagues 34 in 66 patients with MF and SS with most patients having advancedstage MF/SS (IIB-IVB). Patients were included if they had received 150 to 300 mg/m 2 daily within the study period. Other treatment modalities, such as radiation or extracorporeal photopheresis (ECP), were used in some patients. Twenty-eight patients completed at least 1 month of treatment with bexarotene as monotherapy, and in these patients, 46% achieved a clinical response, with 14% (4 patients) achieving a CR and 32% (9 patients) achieving a partial response (PR). In patients treated with bexarotene in combination with other treatment modalities, the CR rate was 5% and PR rate was 37%. Bexarotene appears to have more potent activity in MF compared with its predecessors, but not all patients respond to monotherapy and some fail to maintain remission, prompting investigation into its use in combination with other agents. Bexarotene is available as a 75-mg capsule.
Alitretinoin is another synthetically derived retinoid (9-cis retinoic acid), which can bind to both RAR and RXR, hence its classification as a panretinoic receptor agonist. 1 It was approved in 1999 by the FDA for topical use in localized AIDSrelated Kaposi sarcoma and has been available in Europe since 2008 as an oral formulation for the treatment of refractory severe chronic hand dermatitis. 35, 36 Oral alitretinoin has been used for treatment of MF as reported in a case series of 2 patients, 1 with refractory disease, resulting in PRs and no significant side effects. 37 More recently, a retrospective study described efficacy of alitretinoin (10 or 30 mg daily) when combined with other therapies (including topical steroids, topical calcineurin inhibitors, phototherapy, IFNalpha, and/or photopheresis) in 10 patients with MF (stages IA-IIB) and 1 patient with SS (4 CRs and 6 PRs). Side effects were uncommon and included headache, dyslipidemia, and low thyroid-stimulating hormone (TSH) without other thyroid abnormalities. 38 This drug holds significant promise for the treatment of MF/SS, but further studies are needed to investigate its efficacy and safety in this patient population.
Retinoids also have been studied in combination with other treatment modalities (both skin directed and other systemic agents) in MF/SS in an attempt to improve response rates, prolong remission, and decrease adverse effects by using lower doses with nonoverlapping toxicities. Of note, the limitation of these combination studies are that most of them were not controlled, were without comparator arm, had a limited number of patients, and were performed before International Society of Cutaneous Lymphomas (ISCL)/European Organization for the Research and Treatment of Cancer (EORTC) revisions in CTCL staging (2007) and ISCL/EORTC/US Cutaneous Lymphoma Consortium uniform response criteria definitions (2010), thus making it difficult to accurately compare response rates. 39, 40 Furthermore, because of the paucity of data, it remains unclear if combination therapies are definitively superior to monotherapy. 41 Systemic retinoids combined with skin-directed therapy, such as phototherapy (ultraviolet B [UVB]) or psoralen with ultraviolet A phototherapy (PUVA), referred to as Re-UVB or Re-PUVA are well-known combination therapies for many skin conditions (psoriasis, eczema). In MF/SS, isotretinoin was studied in combination with PUVA, with high response rates in 66 patients, with CR in 72% of patients. Although the clinical response was similar to PUVA alone, the study found that fewer UVA treatments were needed for response when the combination was used. 42 PUVA also was combined with acitretin in 42 patients with CTCL, producing a CR rate of 38%. This was significantly lower compared with the comparator arm of PUVA with IFN, which had a CR rate at 70%. 43 Despite occasional association with photosensitivity in the early clinical studies, since its FDA approval in 1999, bexarotene has been combined successfully with phototherapy in patients with CTCL. In patients with MF stage IA-IIB, combination of low-dose bexarotene (75 mg per day) with PUVA led to clinical response in all patients with CR seen in 63% of patients. 44 In a prospective study of 14 patients with relapsed or treatmentrefractory MF (stage IA-III), patients were treated with bexarotene at 150 to 300 mg per day concurrently with PUVA. Overall response rate was 67%, with 29% CRs. 45 In a large randomized controlled trial comparing PUVA versus bexarotene plus PUVA (EORTC 21011), 87 patients with stage IB/ IIA MF were randomized to each treatment group but no significant difference in response rate (71% PUVA vs 77% combination arm) or response duration (9.7 PUVA vs 5.8 months combination) was found. 46 Bexarotene also has been combined with narrow-band UVB (NBUVB) therapy in case reports. One patient with stage IB plaque-stage MF was treated successfully with low-dose bexarotene (75 mg daily) and NBUVB treatment 3 times weekly. The patient was previously treatment refractory and NBUVB was used in place of PUVA because of the history of multiple basal cell carcinomas. 47 Another case report in a patient with plaque-stage MF responded to a combination of bexarotene 300 mg daily with NBUVB. The disease flared when either bexarotene or NBUVB was discontinued, suggesting a possible synergistic or additive effect. 48 Combination trials using retinoids with other systemics, such as IFNs, have been reported by various investigators. This combination is attractive because of synergistic effects of retinoid stimulation of Th1 activity through IL-12 production and inhibition of Th2 response by IFN-alpha and IFN-gamma. 49 Isotretinoin at 1 mg/kg per day was combined successfully with IFN-alfa-2b 2 million units (MU) 3 times weekly in 7 patients with clinical objective response (OR) seen in 57% of patients (29% achieving CR). 50 Isotretinoin also was studied in combination with IFN-alfa as induction therapy together with total-body electron beam radiation and chemotherapy in 28 patients. Overall response in this study was 82%, with 71% achieving CR. 51 Isotretinoin at 1 mg/kg per day has been investigated in combination with 3 MU daily of IFN-alfa in 18 patients with MF/SS. 52 Patients in this study had advancedstage disease (IIB-IV) and were found to have OR rates of 33% with half the responders having SS. It appears that the combination was well tolerated.
Bexarotene has been investigated in a phase II trial in combination with IFN-alfa in 22 patients with MF/SS. Most of the patients in this study had advanced-stage disease (with 86% of patients having stage II-IV disease). Patients were treated initially with bexarotene 300 mg/m 2 per day alone for 8 weeks followed by the addition of IFN-alfa-2b at 3 to 5 MU 3 times weekly for 8 additional weeks if CR was not achieved with bexarotene alone. No patient achieved CR during the first 8 weeks of treatment with bexarotene alone. The overall response rate was 39%, with 1 patient achieving CR. Of note, 4 additional responses were observed with the addition IFN in the second stage of the study, with 1 patient initially having PR to bexarotene alone converting to CR. 53 ECP is a treatment modality highly effective in patients with SS with treatment responses as a monotherapy reported at 60% and 19% CR. 54 Bexarotene at dosages ranging from 225 to 750 mg per day or up to 300 mg/m 2 daily in combination with ECP led to high response rates of 75% to 80% in small studies. 49, 55 In another study in patients with SS, bexarotene at 150 mg per day was added, as part of a multimodality approach to treatment, to monthly ECP, PUVA with and without IFN-gamma or alfa 3 times weekly producing CRs in 3 of 5 patients and PR in the other 2 patients. 56 Retinoids and rexinoids also have been used in combination with other biologic and chemotherapeutic agents active against MF/SS. The combination of bexarotene in combination with denileukin diftitox is believed to be synergistic, as retinoids have the ability to enhance the expression of high-affinity IL-2 receptor and thereby increase the susceptibility to denileukin diftitox. 4 This effect was observed at bexarotene dosages of 150 mg per day or higher. Fourteen patients with MF/SS treated with the combination of bexarotene 75 to 375 mg per day and denileukin diftitox 18 mg/kg per day 3 times every 21 days, had an overall response rate of 67%, including 29% with a CR. 57 Bexarotene was studied in combination with vorinostat, a histone deacetylase inhibitor, in a combination phase I/II study in 23 patients with MF/SS in stages IB or higher. The maximum tolerated dosage in the phase I part of the study was 200 mg per day of vorinostat and 300 mg/m 2 per day of bexarotene. Patients in the phase II part of the study were treated with 400 mg per day of vorinostat and 150 mg/m 2 per day of bexarotene. Overall response was 26% (7% in phase I of the study and 33% in phase II). This OR rate was similar to patients treated with vorinostat monotherapy. However, improvement in pruritus was reported in several patients. More than 20% of patients required discontinuation from the trial because of adverse effects, but adverse effects reported (neutropenia, diarrhea, hypertriglyceridemia) did not appear to correlate with the higher dosages used in the second phase of the study. 58 Bexarotene also has been studied in MF/SS in combination with chemotherapy agents, such as methotrexate (MTX) and pralatrexate. In a retrospective study of 12 patients with MF (stage IA-IIB) who were treated with bexarotene at dosages of 75 to 300 mg per day and MTX at 5 to 30 mg per week, overall response was 66% with 8% achieving CR. 59 Another study compared pralatrexate with the combination of bexarotene at 150 to 300 mg/m 2 daily and pralatrexate 15 mg/m 2 weekly. Overall response was seen in 33% of patients treated with pralatrexate alone compared with 50% in the combination group. 60 Clinical responses with the combination appear to be higher compared with the individual chemotherapy agents alone. However, not all combination trials demonstrate increased efficacy with the addition of retinoids. In a recently published study evaluating the combination of gemcitabine at 1000 mg/m 2 intravenously on days 1 and 8 every 21 days with oral bexarotene at 300 mg/m 2 per day in 35 predominantly advanced-stage (IB-IVA) CTCL, resulted in interruption of the trial when lower responses were revealed at interim analysis when compared with single-agent gemcitabine. 61 The prominent studies involving the retinoids and rexinoid for treatment of MF/SS are listed in Table 2 .
Resistance to retinoids has been reported in the literature. In vitro evaluation of malignant T cells found that malignant cells from as high as 33% of patients with SS are intrinsically resistant to bexarotene. 62 The mechanism of bexarotene resistance was investigated in a patient who initially responded to treatment but later developed disease relapse. Malignant T cells obtained from this patient at baseline underwent apoptosis with exposure to bexarotene, but cells obtained at relapse did not. No genetic coding alterations in the RXR receptors were found to suggest that mutation of the receptor was responsible for loss Abbreviations: CR, complete response; CT, chemotherapy; CTCL, cutaneous T-cell lymphoma; MF, mycosis fungoides; NA, not available; NBUVB, narrow band UVB; OR, objective response; PR, partial response; PUVA, psoralen plus UVA; SS, Sé zary syndrome; TSEB, total-body skin electron beam radiation.
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of activity. A decline in the levels of RXR receptor expression on cells, which is the receptor target for bexarotene, was found as a possible mechanism. 63 
ADVERSE EFFECTS
Retinoids have a unique side-effect profile compared with traditional cytotoxic agents. In clinical studies of bexarotene, the most common adverse effects are dyslipidemia, which has been reported to occur in 100% of patients, and secondary hypothyroidism, reported in 40% to 100% of patients taking bexarotene. 1 Other common side effects of bexarotene include liver function test abnormalities and dose-dependent leukopenia and neutropenia, and rarely, gastrointestinal disturbances. Dyslipidemia also is common in patients receiving isotretinoin. Table 3 is a list of common side effects associated with bexarotene. In contrast to the adverse effects seen in RXR agonists, side effects associated with RAR agonists seen in clinical studies in patients with CTCL include xerosis (dose-limiting), cheilitis, headaches, and arthralgias/myalgias. See Table 4 for side effects associated with isotretinoin. Because of teratogenic effects, all retinoids and rexinoids should be avoided in pregnant patients or in patients who wish to become pregnant.
Dyslipidemia is a dose-dependent and sometimes dose-limiting adverse reaction to both retinoids and rexinoids. This is typically manifested as hypertriglyceridemia and less commonly hypercholesterolemia. Activation of RAR leads to secretion and decreased catabolism of triglyceride particles leading to hypertriglyceridemia and resulting decrease in high-density lipopoprotein. 64 The binding of agonists to RXR has been shown to result in increased apoCIII synthesis, a hepatic protein that binds to lipids in the plasma and aids in hepatic uptake of triglyceride particles. It also decreases lipoprotein lipase activity, which hydrolyzes triglycerides into fatty acids. 65 Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that are part of the superfamily of receptors that also includes retinoid receptors and others. These receptors are strongly expressed in the skin and sebaceous glands and are involved in oxidative pathways for fatty acids. 65 Retinoic X receptors form heterodimers with PPARs and transactivation by rexinoids are believed to influence lipid metabolism. 1 Triglyceride elevation also is regulated by transactivation of LXR (Liver X receptor)/RXR heterodimers by sterol regulatory element-binding proteins, which are transcription regulators involved in cholesterol biosynthesis. 1 The LXR acts by controlling cholesterol metabolism in the liver as well as reverse cholesterol transport from the peripheral tissues to the liver by increasing plasma lipids. Activation of LXR on RXR heterodimers may play only a small part in the complex pathway of the influence retinoids have on metabolism of not only lipids, but also of glucose and fatty acids. 1 In patients receiving bexarotene as monotherapy at 300 mg/m 2 daily, hypertriglyceridemia was found in 83% of patients, with 2 of 70 patients developing pancreatitis due to the markedly elevated triglyceride levels. 49 Of interest, it was reported by Talpur and colleagues 49 in 2002 that higher response rates to bexarotene were associated with use of lipid-lowering agents, with the highest response rates seen in patients treated with atorvastatin and fenofibrate. The higher response rate in these patients may be merely a reflection of the higher doses of bexarotene used (as dyslipidemia is a dose-dependent phenomenon) or perhaps higher sensitivity to bexarotene, which parallels dose response. In contrast, patients who were treated with the lipid-lowering agent gemfibrozil had more severe hypertriglyceridemia and elevated bexarotene serum levels. Its use is contraindicated with bexarotene because it inhibits the oxidative metabolism of the drug, thereby increasing toxicity. 49 In one case series of 102 subjects on isotretinoin, patients with predisposing conditions, such as truncal obesity, hyperinsulinemia, or family history of hypertriglyceridemia, were more likely to develop retinoid-induced hypertriglyceridemia. 66 Patients receiving either isotretinoin or bexarotene should have baseline lipid evaluation before starting therapy and close monitoring should take place during treatment. In most patients treated with bexarotene, treatment with lipid-lowering agents and adherence to low-fat and low-cholesterol diet are recommended at the onset of treatment.
Central hypothyroidism also is commonly encountered in patients treated with bexarotene. This is caused by suppression of the pituitary production of the TSH. RXRg is the subtype of receptor implicated in rexinoid-induced hypothyroidism and is strongly expressed in the pituitary. In contrast, isotretinoin and acitretin, RAR agonists, do not have effects on TSH levels and hypothyroidism. 2 Alitretinoin affects both RAR and RXR receptors, so it also may have effects on the thyroid hormone axis. Similar to retinoid-induced hyperlipidemia, bexarotene-induced hypothyroidism also appears to be dose dependent and reversible. In patients with normal thyroid function before starting treatment with bexarotene, serum TSH returns to normal in most patients as early as 8 days after stopping bexarotene. 67 Because bexarotene patients typically require doses higher than replacement thyroid doses used in hypothyroidism from other causes, it has been suggested that an increase in metabolism of thyroid hormone also may play a role, perhaps through induction of liver metabolic oxidative enzymes by retinoids. 2, 68 Patients should be started on empiric thyroid supplementation at onset of treatment with bexarotene (25-50 mg daily) and increased based on monthly serum-free thyroxine (free T4) levels. TSH remains suppressed while on bexarotene, even with adequate levothyroxine supplementation so the TSH should not be used as the basis by which one adjusts levothyroxine dose. Dose-dependent leukopenia and neutropenia can be observed in 10% of patients, but in contrast to neutropenia observed after cytotoxic chemotherapy, bexarotene neutropenia is not typically associated with increased opportunistic infections because neutrophils are functionally normal. Given this, in our patients with MF/SS who have no previous history of cytotoxic chemotherapy, we do not dose reduce bexarotene unless absolute neutrophil count is less than 500/mL (Ellen Kim, personal communication, 2015) .
Alitretinoin has been associated with a lower incidence of dyslipidemia and/or suppression of the thyroid axis as compared with isotretinoin or bexarotene, usually not requiring treatment for these side effects. 35 The mechanism explaining this difference in side-effect profile is not known. 37 No definitive guidelines exist for monitoring or management of adverse effects associated with retinoids and rexinoids. Isotretinoin is contraindicated in patients who are pregnant and should be used with caution in patients who have history of uncontrolled psychiatric illness, inflammatory bowel disease, and osteoporosis. Patients who are being treated with isotretinoin in the United States should follow monitoring as per the iPLEDGE (a mandatory distribution program for isotretinoin in the United States) program. This includes pregnancy monitoring for female patients with childbearing potential at baseline and monthly. Patients receiving isotretinoin should avoid concomitant use of tetracycline class of antibiotics due to the increased risk of pseudotumor cerebri. We also recommend baseline laboratory testing such as complete blood count, liver function tests, and lipid profile while on therapy. Acitretin and bexarotene are also contraindicated in pregnancy and should be used with caution in patients with liver disease, history of alcohol abuse, or uncontrolled hyperlipidemia. Female patients should avoid becoming pregnant for at least 3 years after discontinuation of the acitretin. This should be considered before initiation of treatment in any female patient who is of childbearing age. Use of alcohol during treatment with acitretin results in conversion of acitretin to etretinate and can result in prolonged elimination of the retinoid. 69 In patients on treatment with bexarotene, additional monitoring of free thyroxine (free-T4) levels and not TSH is required (TSH is typically suppressed in central hypothyroidism and is not reliable as a measure of thyroid function in patients on the medication). Bexarotene should not be given in combination with gemfibrozil because of increases in plasma concentration of bexarotene. It is metabolized in the liver via cytochrome p-450 3A4 and when used in combination with 3A4 inhibitors, such as azole class of antifungal agents (ketoconazole, itraconazole) or grapefruit juice or with 3A4 inducers, such as rifampin or phenytoin, alterations in plasma levels of the drug may occur. 70 In all patients receiving retinoids, lifestyle modifications, including exercise and dietary changes that include low-fat diet and limits on alcohol consumption should be advised. Recommended monitoring and management of adverse effects for patients on retinoids and rexinoids are shown in Fig. 2 does not alter life expectancy to aggressive, rapidly progressive disease. Goals of treatment especially in patients with early-stage disease are to induce remission with agents that have a low toxicity profile. The systemic retinoids are an important component of the treatment options for all stages of this disease because of the ease of administration and relative low toxicity profile. Side effects appear to be dose related and should be monitored closely with hyperlipidemia observed with all retinoids, whereas other side effects are more drug or retinoid class specific. For example, central hypothyroidism appears to be limited to RXR agonists and mucocutaneous dryness to RAR agonists. Bexarotene is the only FDA-approved systemic retinoid approved specifically for CTCL but does require additional medications to treat the associated hyperlipidemia and hypothyroidism during the duration of bexarotene treatment. Combination treatment with retinoids and other agents with activity against MF/ SS appear to be well tolerated and associated with high response rates in relapsed or treatmentrefractory patients in small studies and series.
Further high-quality clinical trials are needed in MF/SS patients to confirm whether combination therapies are superior to monotherapy.
